首页 > 最新文献

American journal of clinical and experimental urology最新文献

英文 中文
Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases. 遗传性前列腺癌中的楔形癌和导管内癌:20 例病例的临床和病理分析。
IF 1.2 Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/XOIN3964
Yuhao Zhang, Yutao Zhang, Minjing Shi, Xiaoyan Liu, Han Zhang, Ping Zhao, Guoping Ren

Cribiform and intraductal carcinoma are patterns of aggressive prostate carcinoma. This study investigated the clinical and pathological features of hereditary prostate cancer. Twenty cases of hereditary prostate cancer from 11 family lines treated at the First Affiliated Hospital of Zhejiang University School of Medicine between 2016-2022 were included to summarize the clinical and pathological features by analyzing clinical information including follow up the survival of the patients and pathological features. Of the 20 hereditary prostate cancer cases, 19 were radical prostate specimens and 1 was a biopsy specimen. The mean age at diagnosis of the patients was 67.55 years and the mean PSA was 15.44 ng/ml, of which 10 cases had PSA ≥ 10 ng/ml and 5 cases had PSA ≥ 20 ng/ml. Of the 19 radical prostate specimens, Gleason cribriform pattern (Gleason grade 4) of PCa is observed in 15 cases (78.95%), and intraductal carcinoma, usually a rare form, is seen in 9 cases (47.3%). Two cases demonstrated pelvic lymph node metastasis, and 7 cases (35%) belonged to high-risk or very high-risk PCa. One case (5.26%) showed partial deletion of expression of RB1, and 13 cases (68.42%) showed deletion of expression of PTEN. Follow-up was 4-90 months, 2 cases had biochemical recurrence and 1 case died from prostate cancer. The mean age at diagnosis of this group of patients with hereditary prostate cancer was 67.55 years, the mean preoperative PSA was 15.44 ng/ml, and their histomorphology was characterized by a high percentage of intraductal carcinoma and cribriform pattern of the prostate.

楔形癌和导管内癌是侵袭性前列腺癌的模式。本研究调查了遗传性前列腺癌的临床和病理特征。纳入浙江大学医学院附属第一医院2016-2022年间收治的11个家系的20例遗传性前列腺癌患者,通过分析患者的随访生存期等临床资料和病理特征,总结遗传性前列腺癌的临床和病理特征。在20例遗传性前列腺癌病例中,19例为前列腺癌根治术标本,1例为活检标本。患者确诊时的平均年龄为67.55岁,平均PSA为15.44纳克/毫升,其中10例PSA≥10纳克/毫升,5例PSA≥20纳克/毫升。在 19 例前列腺癌根治术标本中,15 例(78.95%)观察到 PCa 的格里森楔形模式(格里森 4 级),9 例(47.3%)观察到导管内癌,导管内癌通常是一种罕见的形式。2 例病例出现盆腔淋巴结转移,7 例(35%)属于高危或极高危 PCA。1例(5.26%)表现为RB1部分缺失,13例(68.42%)表现为PTEN缺失。随访时间为 4-90 个月,2 例生化复发,1 例死于前列腺癌。这组遗传性前列腺癌患者确诊时的平均年龄为 67.55 岁,术前 PSA 平均值为 15.44 ng/ml,组织形态学特征为导管内癌和前列腺楔形形态比例较高。
{"title":"Cribiform and intraductal carcinoma in hereditary prostate cancer: clinical and pathological analysis of 20 cases.","authors":"Yuhao Zhang, Yutao Zhang, Minjing Shi, Xiaoyan Liu, Han Zhang, Ping Zhao, Guoping Ren","doi":"10.62347/XOIN3964","DOIUrl":"10.62347/XOIN3964","url":null,"abstract":"<p><p>Cribiform and intraductal carcinoma are patterns of aggressive prostate carcinoma. This study investigated the clinical and pathological features of hereditary prostate cancer. Twenty cases of hereditary prostate cancer from 11 family lines treated at the First Affiliated Hospital of Zhejiang University School of Medicine between 2016-2022 were included to summarize the clinical and pathological features by analyzing clinical information including follow up the survival of the patients and pathological features. Of the 20 hereditary prostate cancer cases, 19 were radical prostate specimens and 1 was a biopsy specimen. The mean age at diagnosis of the patients was 67.55 years and the mean PSA was 15.44 ng/ml, of which 10 cases had PSA ≥ 10 ng/ml and 5 cases had PSA ≥ 20 ng/ml. Of the 19 radical prostate specimens, Gleason cribriform pattern (Gleason grade 4) of PCa is observed in 15 cases (78.95%), and intraductal carcinoma, usually a rare form, is seen in 9 cases (47.3%). Two cases demonstrated pelvic lymph node metastasis, and 7 cases (35%) belonged to high-risk or very high-risk PCa. One case (5.26%) showed partial deletion of expression of RB1, and 13 cases (68.42%) showed deletion of expression of PTEN. Follow-up was 4-90 months, 2 cases had biochemical recurrence and 1 case died from prostate cancer. The mean age at diagnosis of this group of patients with hereditary prostate cancer was 67.55 years, the mean preoperative PSA was 15.44 ng/ml, and their histomorphology was characterized by a high percentage of intraductal carcinoma and cribriform pattern of the prostate.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary ureteral adenocarcinoma in a patient with previous gastric adenocarcinoma: a rare nonmetastatic case. 曾患有胃腺癌的患者的原发性输尿管腺癌:一个罕见的非转移病例。
IF 1.2 Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/XPDS8196
Reza Kazemi, Faezeh Jandaghi, Farzaneh Montazeri

Upper urinary tract adenocarcinoma is a rare malignancy with a challenging diagnosis and limited treatment options. This paper presents a rare case of primary ureteral adenocarcinoma, an exceptionally uncommon malignancy typically associated with genitourinary or extra-genitourinary tumors. The 53-year-old patient, with a history of gastric adenocarcinoma and prior chemotherapy, developed left flank pain. Imaging revealed a tumor in the distal ureter, leading to a left radical nephroureterectomy. Histopathology confirmed an intestinal-type adenocarcinoma of the upper urinary tract. Unique to this case, the adenocarcinoma originated separately from the stomach. Despite planning adjuvant chemotherapy, the patient's deteriorating condition led to palliative care, and he passed away three months post-diagnosis. The paper underscores the challenges in diagnosing and treating such rare malignancies, emphasizing the need for further research to understand their etiology and optimal management.

上尿路腺癌是一种罕见的恶性肿瘤,诊断困难,治疗方案有限。本文介绍了一例罕见的原发性输尿管腺癌,这是一种非常不常见的恶性肿瘤,通常与泌尿生殖系统肿瘤或泌尿生殖系统外肿瘤相关。53 岁的患者有胃腺癌病史,曾接受过化疗。影像学检查发现输尿管远端有肿瘤,因此进行了左侧根治性肾切除术。组织病理证实为上尿路肠型腺癌。该病例的独特之处在于,腺癌是从胃部单独生长出来的。尽管患者计划接受辅助化疗,但由于病情恶化,不得不接受姑息治疗,最终在确诊后三个月去世。这篇论文强调了诊断和治疗这类罕见恶性肿瘤的挑战,强调需要进一步研究以了解其病因和最佳治疗方法。
{"title":"Primary ureteral adenocarcinoma in a patient with previous gastric adenocarcinoma: a rare nonmetastatic case.","authors":"Reza Kazemi, Faezeh Jandaghi, Farzaneh Montazeri","doi":"10.62347/XPDS8196","DOIUrl":"10.62347/XPDS8196","url":null,"abstract":"<p><p>Upper urinary tract adenocarcinoma is a rare malignancy with a challenging diagnosis and limited treatment options. This paper presents a rare case of primary ureteral adenocarcinoma, an exceptionally uncommon malignancy typically associated with genitourinary or extra-genitourinary tumors. The 53-year-old patient, with a history of gastric adenocarcinoma and prior chemotherapy, developed left flank pain. Imaging revealed a tumor in the distal ureter, leading to a left radical nephroureterectomy. Histopathology confirmed an intestinal-type adenocarcinoma of the upper urinary tract. Unique to this case, the adenocarcinoma originated separately from the stomach. Despite planning adjuvant chemotherapy, the patient's deteriorating condition led to palliative care, and he passed away three months post-diagnosis. The paper underscores the challenges in diagnosing and treating such rare malignancies, emphasizing the need for further research to understand their etiology and optimal management.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urine-derived stem cells genetically modified with IGF1 improve muscle regeneration. 经 IGF1 基因修饰的尿源干细胞可改善肌肉再生。
IF 1.2 Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/QSKH2686
Hualin Yi, Gang Chen, Shuai Qiu, Joshua T Maxwell, Guiting Lin, Tracy Criswell, Yuanyuan Zhang

Objective: In this study we aimed to determine the impact of human urine derived stem cells (USC) and genetically modified USC that were designed to overexpress myogenic growth factor IGF1 (USCIGF), on the regenerative capacity of cardiotoxin (CTX)-injured murine skeletal muscle.

Methods: We overexpressed IGF1 in USC and investigated the alterations in myogenic capacity and regenerative function in cardiotoxin-injured muscle tissues.

Results: Compared with USC alone, USCIGF1 activated the IGF1-Akt-mTOR signaling pathway, significantly improved myogenic differentiation capacity in vitro, and enhanced the secretion of myogenic growth factors and cytokines. In addition, IGF1 overexpression increased the ability of USC to fuse with skeletal myocytes to form myotubes, regulated the pro-regenerative immune response and inflammatory cytokines, and increased myogenesis in an in vivo model of skeletal muscle injury.

Conclusion: Overall, USC genetically modified to overexpress IGF1 significantly enhanced skeletal muscle regeneration by regulating myogenic differentiation, paracrine effects, and cell fusion, as well as by modulating immune responses in injured skeletal muscles in vivo. This study provides a novel perspective for evaluating the myogenic function of USC as a nonmyogenic cell source in skeletal myogenesis. The combination of USC and IGF1 expression has the potential to provide a novel efficient therapy for skeletal muscle injury and associated muscular defects in patients with urinary incontinence.

研究目的在这项研究中,我们旨在确定人尿衍生干细胞(USC)和基因修饰USC(旨在过表达肌原生长因子IGF1(USCIGF))对心脏毒素(CTX)损伤小鼠骨骼肌再生能力的影响:方法:我们在USC中过表达了IGF1,并研究了心脏毒素损伤肌肉组织的肌生成能力和再生功能的变化:结果:与单独表达 USC 相比,USCIGF1 激活了 IGF1-Akt-mTOR 信号通路,显著提高了体外成肌分化能力,并增强了成肌生长因子和细胞因子的分泌。此外,在体内骨骼肌损伤模型中,IGF1的过表达提高了USC与骨骼肌细胞融合形成肌管的能力,调节了促再生免疫反应和炎性细胞因子,并增加了肌生成:总之,转基因过表达 IGF1 的 USC 可通过调节肌原分化、旁分泌效应和细胞融合,以及调节体内骨骼肌损伤的免疫反应,显著促进骨骼肌再生。这项研究为评估 USC 作为骨骼肌生成过程中的非生肌细胞源的生肌功能提供了一个新的视角。USC 和 IGF1 表达的结合有望为尿失禁患者的骨骼肌损伤和相关肌肉缺陷提供一种新型高效疗法。
{"title":"Urine-derived stem cells genetically modified with IGF1 improve muscle regeneration.","authors":"Hualin Yi, Gang Chen, Shuai Qiu, Joshua T Maxwell, Guiting Lin, Tracy Criswell, Yuanyuan Zhang","doi":"10.62347/QSKH2686","DOIUrl":"10.62347/QSKH2686","url":null,"abstract":"<p><strong>Objective: </strong>In this study we aimed to determine the impact of human urine derived stem cells (USC) and genetically modified USC that were designed to overexpress myogenic growth factor IGF1 (USC<sup>IGF</sup>), on the regenerative capacity of cardiotoxin (CTX)-injured murine skeletal muscle.</p><p><strong>Methods: </strong>We overexpressed IGF1 in USC and investigated the alterations in myogenic capacity and regenerative function in cardiotoxin-injured muscle tissues.</p><p><strong>Results: </strong>Compared with USC alone, USC<sup>IGF1</sup> activated the IGF1-Akt-mTOR signaling pathway, significantly improved myogenic differentiation capacity in vitro, and enhanced the secretion of myogenic growth factors and cytokines. In addition, IGF1 overexpression increased the ability of USC to fuse with skeletal myocytes to form myotubes, regulated the pro-regenerative immune response and inflammatory cytokines, and increased myogenesis in an in vivo model of skeletal muscle injury.</p><p><strong>Conclusion: </strong>Overall, USC genetically modified to overexpress IGF1 significantly enhanced skeletal muscle regeneration by regulating myogenic differentiation, paracrine effects, and cell fusion, as well as by modulating immune responses in injured skeletal muscles in vivo. This study provides a novel perspective for evaluating the myogenic function of USC as a nonmyogenic cell source in skeletal myogenesis. The combination of USC and IGF1 expression has the potential to provide a novel efficient therapy for skeletal muscle injury and associated muscular defects in patients with urinary incontinence.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in experimental autoimmune prostatitis: insights into pathogenesis, therapeutic strategies, and redefinition. 实验性自身免疫性前列腺炎的发展趋势:对发病机制、治疗策略和重新定义的见解。
IF 1.2 Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/OUJJ3710
Robbie Sj Manuel, Chad M Vezina

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPSS) is a debilitating condition characterized by prostate inflammation, pain and urinary symptoms. The immune system's response to self-antigens is a contributing factor to CP/CPSS. In this review, we examine the use of experimental autoimmune prostatitis (EAP) in rodents to model salient features of autoimmune mediated CP/CPSS. By exploring etiological factors, immunological mechanisms, and emerging therapeutic strategies, our aim is to enhance our understanding of CP/CPSS pathogenesis and promote the development of strategies to test innovative interventions using the EAP pre-clinical model.

慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPSS)是一种以前列腺炎症、疼痛和泌尿系统症状为特征的衰弱性疾病。免疫系统对自身抗原的反应是导致 CP/CPSS 的一个因素。在这篇综述中,我们研究了利用啮齿动物实验性自身免疫性前列腺炎(EAP)来模拟自身免疫介导的 CP/CPSS 的显著特征。通过探讨病因学因素、免疫学机制和新出现的治疗策略,我们的目的是加深对 CP/CPSS 发病机制的了解,并促进策略的开发,从而利用 EAP 临床前模型试验创新性干预措施。
{"title":"Trends in experimental autoimmune prostatitis: insights into pathogenesis, therapeutic strategies, and redefinition.","authors":"Robbie Sj Manuel, Chad M Vezina","doi":"10.62347/OUJJ3710","DOIUrl":"10.62347/OUJJ3710","url":null,"abstract":"<p><p>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPSS) is a debilitating condition characterized by prostate inflammation, pain and urinary symptoms. The immune system's response to self-antigens is a contributing factor to CP/CPSS. In this review, we examine the use of experimental autoimmune prostatitis (EAP) in rodents to model salient features of autoimmune mediated CP/CPSS. By exploring etiological factors, immunological mechanisms, and emerging therapeutic strategies, our aim is to enhance our understanding of CP/CPSS pathogenesis and promote the development of strategies to test innovative interventions using the EAP pre-clinical model.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer. 膀胱癌中的转录因子性别决定区 Y-box 2 (SOX2)。
IF 1.2 Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/MEQO6014
Rachel L Griffin, Lauren Shuman, Hironobu Yamashita, Qingqing Wu, Guoli Chen, Ryan M Brown, Don Vander Griend, David J DeGraff, Joshua I Warrick

Sex-determining region Y-box 2 (SOX2) is a transcription factor with a central role in embryologic development. SOX2 is also an oncogene in several cancer types. Prior work by our group has shown SOX2 activity associates with cell cycle dysregulation in early-stage bladder cancer. The present study was thus undertaken to broadly investigate SOX2 in bladder cancer, with emphasis on associations with tumor stage, clinical outcomes, and tumorigenicity. Gene expression was quantified by immunohistochemistry in an established tissue microarray (n=303 cystectomy specimens, all stages) and whole tissue sections of noninvasive papillary urothelial carcinoma (n=25). Gene expression by RNA sequencing was evaluated in non-muscle invasive and muscle-invasive cohorts from publicly available repositories. By immunohistochemistry, SOX2 was expressed in 40% of whole tissue sections of noninvasive papillary carcinoma, which correlated with SOX2 expression by RNA sequencing (r=0.6, P=0.001, Spearman correlation). Expression tended to be focal (median H-score =6). SOX2 was expressed in only 9% of TMA cases, consistent with focal expression. SOX2 expression was substantially higher in muscle-invasive compared with noninvasive papillary urothelial carcinoma by RNA sequencing (P<0.001, Wilcoxon rank sum test). SOX2 expression associated with stage progression in lamina-propria invasive cancers (hazard ratio =2, P=0.05, Cox model, binary, RNA sequencing) but not noninvasive papillary cancers (P=0.5, Cox model, binary, RNA sequencing). SOX2 expression did not associate with overall survival in muscle-invasive carcinoma. Activity of SOX2 in bladder cancer was tested in vivo using murine allografts created with MB49 cells that express human SOX2 (MB49-SOX). MB49-SOX allografts expressed this protein focally by immunohistochemistry, much like human tumors. Compared with controls, MB49 allografts demonstrated larger tumor size (P=0.03, Wilcoxon rank sum test) and higher tumor burden in mesenteric metastases (P=0.009, Wilcoxon rank sum test). Though SOX2 expression is focal within tumors, it may drive tumorigenesis, increase growth rate, and promote aggressive features of bladder cancer, particularly stage progression of early-stage disease.

性别决定区 Y-box 2(SOX2)是一种转录因子,在胚胎发育过程中起着核心作用。SOX2 也是几种癌症类型的致癌基因。我们小组之前的研究表明,在早期膀胱癌中,SOX2 的活性与细胞周期失调有关。因此,本研究对膀胱癌中的 SOX2 进行了广泛调查,重点研究其与肿瘤分期、临床结果和致瘤性的关系。通过免疫组化方法对已建立的组织芯片(303 例膀胱切除标本,所有分期)和非浸润性乳头状尿路上皮癌(25 例)的整个组织切片中的基因表达进行了量化。通过 RNA 测序评估了来自公开资料库的非肌层浸润性和肌层浸润性队列中的基因表达。通过免疫组化,40%的非浸润性乳头状癌全组织切片中表达了SOX2,这与RNA测序的SOX2表达相关(r=0.6,P=0.001,Spearman相关性)。表达倾向于局灶性(H-评分中位数=6)。只有 9% 的 TMA 病例表达 SOX2,这与病灶表达一致。通过RNA测序,肌肉浸润性乳头状尿路上皮癌的SOX2表达远高于非浸润性乳头状尿路上皮癌(PSOX2表达与浸润性癌的分期进展相关(危险比=2,P=0.05,Cox模型,二元,RNA测序),但与非浸润性乳头状癌无关(P=0.5,Cox模型,二元,RNA测序)。SOX2的表达与肌肉浸润癌的总生存率无关。使用表达人类 SOX2 的 MB49 细胞(MB49-SOX)创建的鼠异体移植对 SOX2 在膀胱癌中的活性进行了体内测试。通过免疫组化,MB49-SOX 异体移植物局部表达了这种蛋白,与人类肿瘤非常相似。与对照组相比,MB49 异体移植物的肿瘤体积更大(P=0.03,Wilcoxon 秩和检验),肠系膜转移灶的肿瘤负荷更高(P=0.009,Wilcoxon 秩和检验)。虽然SOX2在肿瘤内的表达是局灶性的,但它可能会推动肿瘤发生,增加生长速度,促进膀胱癌的侵袭性特征,尤其是早期疾病的分期进展。
{"title":"The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.","authors":"Rachel L Griffin, Lauren Shuman, Hironobu Yamashita, Qingqing Wu, Guoli Chen, Ryan M Brown, Don Vander Griend, David J DeGraff, Joshua I Warrick","doi":"10.62347/MEQO6014","DOIUrl":"10.62347/MEQO6014","url":null,"abstract":"<p><p>Sex-determining region Y-box 2 (SOX2) is a transcription factor with a central role in embryologic development. SOX2 is also an oncogene in several cancer types. Prior work by our group has shown SOX2 activity associates with cell cycle dysregulation in early-stage bladder cancer. The present study was thus undertaken to broadly investigate SOX2 in bladder cancer, with emphasis on associations with tumor stage, clinical outcomes, and tumorigenicity. Gene expression was quantified by immunohistochemistry in an established tissue microarray (n=303 cystectomy specimens, all stages) and whole tissue sections of noninvasive papillary urothelial carcinoma (n=25). Gene expression by RNA sequencing was evaluated in non-muscle invasive and muscle-invasive cohorts from publicly available repositories. By immunohistochemistry, SOX2 was expressed in 40% of whole tissue sections of noninvasive papillary carcinoma, which correlated with <i>SOX2</i> expression by RNA sequencing (r=0.6, P=0.001, Spearman correlation). Expression tended to be focal (median H-score =6). SOX2 was expressed in only 9% of TMA cases, consistent with focal expression. <i>SOX2</i> expression was substantially higher in muscle-invasive compared with noninvasive papillary urothelial carcinoma by RNA sequencing (P<0.001, Wilcoxon rank sum test). <i>SOX2</i> expression associated with stage progression in lamina-propria invasive cancers (hazard ratio =2, P=0.05, Cox model, binary, RNA sequencing) but not noninvasive papillary cancers (P=0.5, Cox model, binary, RNA sequencing). <i>SOX2</i> expression did not associate with overall survival in muscle-invasive carcinoma. Activity of SOX2 in bladder cancer was tested <i>in vivo</i> using murine allografts created with MB49 cells that express human SOX2 (MB49-SOX). MB49-SOX allografts expressed this protein focally by immunohistochemistry, much like human tumors. Compared with controls, MB49 allografts demonstrated larger tumor size (P=0.03, Wilcoxon rank sum test) and higher tumor burden in mesenteric metastases (P=0.009, Wilcoxon rank sum test). Though SOX2 expression is focal within tumors, it may drive tumorigenesis, increase growth rate, and promote aggressive features of bladder cancer, particularly stage progression of early-stage disease.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating symptom severity and urinary cytokine levels in interstitial cystitis/bladder pain syndrome patients, with and without Hunner's lesions. 评估间质性膀胱炎/膀胱疼痛综合征患者的症状严重程度和尿液细胞因子水平,包括有无亨纳病变。
IF 1.2 Pub Date : 2024-04-15 eCollection Date: 2024-01-01 DOI: 10.62347/BLED2401
Bernadette Mm Zwaans, Sabrina Mota, Sarah N Bartolone, Elijah P Ward, Kenneth M Peters, Michael B Chancellor

Purpose: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a condition characterized in part by urinary urgency, frequency, and pain. There is a strong interest in gathering more data to compare and assess the differences in characteristics based on the presence of Hunner's lesions in patients with IC/BPS.

Materials and methods: Using a nationwide crowdsource effort, we collected surveys and urine samples from patients with a history of IC/BPS. Participants completed the Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), Overactive Bladder questionnaire (OABq SF), and pain scores. In addition, participants reported any co-morbidities and lifestyle modifications. Urinary cytokine levels were measured and compared to symptom severity.

Results: 491 participants enrolled: 119 with history of ulcerative Hunner's lesions (UIC), 372 reported no lesions (NHIC), and 2 unknowns. 96.3% were female, and prevalence of UIC was equal for both genders. Average age was higher for UIC vs. NHIC group (P = 0.011), as was the duration since diagnosis (P < 0.001). Symptom scores were elevated in UIC patients (P < 0.001). Both groups widely implemented lifestyle modifications, with dietary changes being most prevalent (70.1%), followed by prescription medication usage (63.1%). More UIC compared to NHIC participants experienced co-morbidities (P = 0.010). Urine samples were analyzed for GRO, IL-6, IL-8, and MCP-1. MCP-1 levels were significantly higher in UIC patients (P = 0.044). Weak positive correlation was found between cytokines and symptom scores.

Conclusions: Patients with UIC and NHIC from across the United States displayed distinct phenotypic and urine biological characteristics. These findings contribute to increased understanding of IC/BPS and may aid in improving our knowledge of the condition.

目的:间质性膀胱炎/膀胱疼痛综合征(IC/BPS)的部分特征是尿急、尿频和尿痛。人们对收集更多数据以比较和评估IC/BPS患者因Hunner病变而产生的特征差异有着浓厚的兴趣:我们通过全国范围内的众包努力,收集了有 IC/BPS 病史患者的调查问卷和尿样。参与者填写了间质性膀胱炎症状指数(ICSI)和问题指数(ICPI)、膀胱过度活动问卷(OABq SF)和疼痛评分。此外,参与者还报告了任何并发症和生活方式改变情况。测量尿液细胞因子水平并与症状严重程度进行比较:结果:491 人参加了研究:119 人有溃疡性亨纳病变史(UIC),372 人报告无病变(NHIC),2 人情况不明。96.3%为女性,男女溃疡性亨纳氏病变发病率相同。UIC 组的平均年龄高于 NHIC 组(P = 0.011),确诊时间也高于 NHIC 组(P < 0.001)。UIC 患者的症状评分较高(P < 0.001)。两组患者都广泛采用了改变生活方式的方法,其中以改变饮食习惯最为普遍(70.1%),其次是使用处方药(63.1%)。与国家卫生信息中心的参与者相比,有更多的尿毒症患者合并有其他疾病(P = 0.010)。对尿液样本进行了 GRO、IL-6、IL-8 和 MCP-1 分析。UIC 患者的 MCP-1 水平明显更高(P = 0.044)。细胞因子与症状评分之间存在微弱的正相关性:结论:美国各地的 UIC 和 NHIC 患者表现出不同的表型和尿液生物学特征。这些发现有助于加深对 IC/BPS 的了解,并有助于提高我们对该疾病的认识。
{"title":"Evaluating symptom severity and urinary cytokine levels in interstitial cystitis/bladder pain syndrome patients, with and without Hunner's lesions.","authors":"Bernadette Mm Zwaans, Sabrina Mota, Sarah N Bartolone, Elijah P Ward, Kenneth M Peters, Michael B Chancellor","doi":"10.62347/BLED2401","DOIUrl":"10.62347/BLED2401","url":null,"abstract":"<p><strong>Purpose: </strong>Interstitial cystitis/bladder pain syndrome (IC/BPS) is a condition characterized in part by urinary urgency, frequency, and pain. There is a strong interest in gathering more data to compare and assess the differences in characteristics based on the presence of Hunner's lesions in patients with IC/BPS.</p><p><strong>Materials and methods: </strong>Using a nationwide crowdsource effort, we collected surveys and urine samples from patients with a history of IC/BPS. Participants completed the Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), Overactive Bladder questionnaire (OABq SF), and pain scores. In addition, participants reported any co-morbidities and lifestyle modifications. Urinary cytokine levels were measured and compared to symptom severity.</p><p><strong>Results: </strong>491 participants enrolled: 119 with history of ulcerative Hunner's lesions (UIC), 372 reported no lesions (NHIC), and 2 unknowns. 96.3% were female, and prevalence of UIC was equal for both genders. Average age was higher for UIC vs. NHIC group (P = 0.011), as was the duration since diagnosis (P < 0.001). Symptom scores were elevated in UIC patients (P < 0.001). Both groups widely implemented lifestyle modifications, with dietary changes being most prevalent (70.1%), followed by prescription medication usage (63.1%). More UIC compared to NHIC participants experienced co-morbidities (P = 0.010). Urine samples were analyzed for GRO, IL-6, IL-8, and MCP-1. MCP-1 levels were significantly higher in UIC patients (P = 0.044). Weak positive correlation was found between cytokines and symptom scores.</p><p><strong>Conclusions: </strong>Patients with UIC and NHIC from across the United States displayed distinct phenotypic and urine biological characteristics. These findings contribute to increased understanding of IC/BPS and may aid in improving our knowledge of the condition.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of Fuhrman pathological grade of renal clear cell carcinoma based on CT texture analysis. 基于 CT 纹理分析预测肾透明细胞癌的 Fuhrman 病理分级
IF 1.2 Pub Date : 2024-02-15 eCollection Date: 2024-01-01
Zhuang Dong, Chao Guan, Xuezhen Yang

Objective: To study the predictive performance of the imaging model based on the texture analysis of CT plain scan in distinguishing between low (grade I and II) and high (grade III and IV) of Fuhrman pathological grade of renal clear cell carcinoma.

Methods: The clinical data of 94 patients with ccRCC who underwent CT scan and were confirmed by biopsy or surgery in TCGA-KIRC public database were retrospectively analyzed. There were 32 cases of low-grade ccRCC and 62 cases of high-grade ccRCC. The patients were randomly divided into training set and verification set according to the proportion of 7:3 by stratified sampling method. The imaging characteristics of ccRCC were calculated in the plain CT images. Lasso regression was used to reduce the dimensionality of the imaging characteristics of the training set, and binary logistic regression was used to construct the prediction model. Bootstrap method was used to verify the training set model and the validation set model, and the area under the receiver operating characteristic (ROC) curve (AUC) was calculated respectively.

Results: Binary logistic regression showed that only imaging features were independent risk factors for predicting the Furhman classification of ccRCC. The predictive model was y = 1/[1 + exp (-z)], z = 1.274 × imaging risk score + 0.072. The results of bootstrap internal validation showed that the AUC of the training group was 0.961 (95% CI: 0.900-0.913). The Hosmer-Lemeshow goodness of fit test showed that the prediction model had a good calibration in the training group (P = 0.416). The AUC of prediction model in validation group was 0.731 (95% CI: 0.500-1.000). The Hosmer-Lemeshow goodness of fit test results showed that the prediction model had a good calibration in the validation group (P = 0.592).

Conclusion: The model based on CT texture analysis has a good predictive effect in differentiating low-grade and high-grade ccRCC and can provide reference for the treatment and prognosis of patients.

目的研究基于CT平扫纹理分析的成像模型在区分肾透明细胞癌Fuhrman病理分级低(I级和II级)和高(III级和IV级)时的预测性能:回顾性分析了 TCGA-KIRC 公共数据库中 94 例接受 CT 扫描并经活检或手术确诊的 ccRCC 患者的临床数据。其中 32 例为低级别 ccRCC,62 例为高级别 ccRCC。通过分层抽样法,按照 7:3 的比例将患者随机分为训练集和验证集。计算普通 CT 图像中 ccRCC 的成像特征。采用拉索回归法降低训练集成像特征的维度,并采用二元逻辑回归法构建预测模型。使用 Bootstrap 方法验证了训练集模型和验证集模型,并分别计算了接收者操作特征曲线(ROC)下面积(AUC):二元逻辑回归结果显示,只有影像学特征是预测ccRCC Furhman分类的独立风险因素。预测模型为 y = 1/[1 + exp (-z)],z = 1.274 × 影像学风险评分 + 0.072。引导内部验证结果显示,训练组的 AUC 为 0.961(95% CI:0.900-0.913)。Hosmer-Lemeshow 拟合优度检验表明,预测模型在训练组具有良好的校准性(P = 0.416)。验证组预测模型的 AUC 为 0.731(95% CI:0.500-1.000)。Hosmer-Lemeshow拟合优度检验结果显示,预测模型在验证组具有良好的校准性(P = 0.592):结论:基于CT纹理分析的模型在区分低级别和高级别ccRCC方面具有良好的预测效果,可为患者的治疗和预后提供参考。
{"title":"Prediction of Fuhrman pathological grade of renal clear cell carcinoma based on CT texture analysis.","authors":"Zhuang Dong, Chao Guan, Xuezhen Yang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To study the predictive performance of the imaging model based on the texture analysis of CT plain scan in distinguishing between low (grade I and II) and high (grade III and IV) of Fuhrman pathological grade of renal clear cell carcinoma.</p><p><strong>Methods: </strong>The clinical data of 94 patients with ccRCC who underwent CT scan and were confirmed by biopsy or surgery in TCGA-KIRC public database were retrospectively analyzed. There were 32 cases of low-grade ccRCC and 62 cases of high-grade ccRCC. The patients were randomly divided into training set and verification set according to the proportion of 7:3 by stratified sampling method. The imaging characteristics of ccRCC were calculated in the plain CT images. Lasso regression was used to reduce the dimensionality of the imaging characteristics of the training set, and binary logistic regression was used to construct the prediction model. Bootstrap method was used to verify the training set model and the validation set model, and the area under the receiver operating characteristic (ROC) curve (AUC) was calculated respectively.</p><p><strong>Results: </strong>Binary logistic regression showed that only imaging features were independent risk factors for predicting the Furhman classification of ccRCC. The predictive model was y = 1/[1 + exp (-z)], z = 1.274 × imaging risk score + 0.072. The results of bootstrap internal validation showed that the AUC of the training group was 0.961 (95% CI: 0.900-0.913). The Hosmer-Lemeshow goodness of fit test showed that the prediction model had a good calibration in the training group (P = 0.416). The AUC of prediction model in validation group was 0.731 (95% CI: 0.500-1.000). The Hosmer-Lemeshow goodness of fit test results showed that the prediction model had a good calibration in the validation group (P = 0.592).</p><p><strong>Conclusion: </strong>The model based on CT texture analysis has a good predictive effect in differentiating low-grade and high-grade ccRCC and can provide reference for the treatment and prognosis of patients.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Follow-up and histocompatibility observation of urethral reconstruction with different materials. 使用不同材料进行尿道重建的随访和组织相容性观察。
IF 1.2 Pub Date : 2024-02-15 eCollection Date: 2024-01-01
Hongtian Sun, Haoxuan Yang, Mingxuan Yang, Qian Li, Wenyong Xue, Jinchun Qi

Objective: Our objective is to observe the long-term surgical results of urethral reconstruction using either pedicled penile flaps or lingual mucosa grafts. We also assess the histocompatibility of the reconstructed urethra.

Materials and methods: Clinical data of patients with anterior urethral stenosis undergoing urethra reconstruction by applying different materials were collected from 2014 to 2022 in the Second Hospital of Hebei Medical University. We assessed their efficacy and the occurrence of complications. Patients who required reoperation due to complications were selected. Sections of the reconstructed urethra created with various materials were excised during repair procedures. The excised tissues underwent hematoxylin-eosin staining and immunohistochemistry. Comparison with the original histological morphology was conducted to evaluate histocompatibility.

Results: 42 of the 55 patients were cured which showed a surgical success rate of 76.36%. The success rate of urethra reconstruction surgery utilizing lingual mucosa is 71.43% and that of surgeries using pedicled penis flaps is 79.41%. The long-term prognosis of the two groups is similar (P > 0.05). Observations show that the histological morphology of the original epithelium gradually disappeared, leading to adaptive changes to the urinary environment with favorable histocompatibility.

Conclusion: The application of lingual mucosal and pedicled penis flaps for urethral reconstruction both have a high surgical success rate. The long-term follow-up results are positive. Both methods are viable for urethral reconstruction and exhibit favorable histocompatibility.

目的:我们的目的是观察使用带蒂阴茎皮瓣或舌粘膜移植物进行尿道重建的长期手术效果。我们还评估了重建尿道的组织相容性:收集2014年至2022年河北医科大学第二医院采用不同材料重建尿道的前尿道狭窄患者的临床资料。我们对其疗效和并发症发生情况进行了评估。选择因并发症需要再次手术的患者。在修复过程中,我们切除了使用不同材料重建的尿道部分。切除的组织进行苏木精-伊红染色和免疫组化。与原始组织学形态进行比较,以评估组织相容性:55例患者中有42例治愈,手术成功率为76.36%。利用舌粘膜进行尿道重建手术的成功率为 71.43%,利用阴茎瓣进行手术的成功率为 79.41%。两组患者的长期预后相似(P>0.05)。观察结果显示,原上皮的组织学形态逐渐消失,导致对泌尿环境的适应性改变,组织相容性良好:结论:应用舌侧粘膜瓣和带蒂阴茎瓣重建尿道的手术成功率都很高。长期随访结果良好。这两种方法都可用于尿道重建,并表现出良好的组织相容性。
{"title":"Follow-up and histocompatibility observation of urethral reconstruction with different materials.","authors":"Hongtian Sun, Haoxuan Yang, Mingxuan Yang, Qian Li, Wenyong Xue, Jinchun Qi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Our objective is to observe the long-term surgical results of urethral reconstruction using either pedicled penile flaps or lingual mucosa grafts. We also assess the histocompatibility of the reconstructed urethra.</p><p><strong>Materials and methods: </strong>Clinical data of patients with anterior urethral stenosis undergoing urethra reconstruction by applying different materials were collected from 2014 to 2022 in the Second Hospital of Hebei Medical University. We assessed their efficacy and the occurrence of complications. Patients who required reoperation due to complications were selected. Sections of the reconstructed urethra created with various materials were excised during repair procedures. The excised tissues underwent hematoxylin-eosin staining and immunohistochemistry. Comparison with the original histological morphology was conducted to evaluate histocompatibility.</p><p><strong>Results: </strong>42 of the 55 patients were cured which showed a surgical success rate of 76.36%. The success rate of urethra reconstruction surgery utilizing lingual mucosa is 71.43% and that of surgeries using pedicled penis flaps is 79.41%. The long-term prognosis of the two groups is similar (P > 0.05). Observations show that the histological morphology of the original epithelium gradually disappeared, leading to adaptive changes to the urinary environment with favorable histocompatibility.</p><p><strong>Conclusion: </strong>The application of lingual mucosal and pedicled penis flaps for urethral reconstruction both have a high surgical success rate. The long-term follow-up results are positive. Both methods are viable for urethral reconstruction and exhibit favorable histocompatibility.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute liver injury and contralateral pleural effusion as two rare complications following percutaneous nephrolithotomy: a case report. 急性肝损伤和对侧胸腔积液是经皮肾镜碎石术后的两种罕见并发症:病例报告。
IF 1.2 Pub Date : 2024-02-15 eCollection Date: 2024-01-01
Reza Kazemi, Faezeh Jandaghi, Farzaneh Montazeri, Hanieh Salehi

Introduction: Percutaneous Nephrolithotomy (PCNL) is a widely used surgical intervention for removing large and complex renal calculi. While considered a safe and effective procedure, it can still lead to severe and rare complications, including bleeding, pulmonary complications, and liver dysfunction.

Case presentation: This case report presents a case who underwent PCNL for a kidney stone and subsequently developed a series of rare and severe complications. Following the PCNL procedure, the patient experienced significant bleeding, a known but uncommon complication of PCNL, pulmonary complications, a common complication that may carry a risk of death, and acute liver failure, an exceedingly rare consequence of PCNL.

Conclusion: In summary, while PCNL is a valuable technique for treating kidney stones, it is not without risk. This case underscores the importance of recognizing and managing rare complications following PCNL surgery, highlighting the need for vigilance, multidisciplinary care, and timely interventions to ensure favorable patient outcomes.

导言:经皮肾镜取石术(PCNL)是一种广泛应用的外科手术,用于清除大块和复杂的肾结石。虽然PCNL被认为是一种安全有效的手术,但它仍可能导致严重而罕见的并发症,包括出血、肺部并发症和肝功能异常:本病例报告介绍了一名因肾结石而接受 PCNL 手术的病例,该病例随后出现了一系列罕见的严重并发症。PCNL 术后,患者出现了大量出血(PCNL 的一种已知但不常见的并发症)、肺部并发症(一种常见的并发症,可能有死亡风险)和急性肝功能衰竭(PCNL 的一种极为罕见的后果):总之,虽然 PCNL 是一种治疗肾结石的重要技术,但并非没有风险。本病例强调了识别和处理 PCNL 手术后罕见并发症的重要性,突出了提高警惕、多学科护理和及时干预的必要性,以确保患者获得良好的治疗效果。
{"title":"Acute liver injury and contralateral pleural effusion as two rare complications following percutaneous nephrolithotomy: a case report.","authors":"Reza Kazemi, Faezeh Jandaghi, Farzaneh Montazeri, Hanieh Salehi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Percutaneous Nephrolithotomy (PCNL) is a widely used surgical intervention for removing large and complex renal calculi. While considered a safe and effective procedure, it can still lead to severe and rare complications, including bleeding, pulmonary complications, and liver dysfunction.</p><p><strong>Case presentation: </strong>This case report presents a case who underwent PCNL for a kidney stone and subsequently developed a series of rare and severe complications. Following the PCNL procedure, the patient experienced significant bleeding, a known but uncommon complication of PCNL, pulmonary complications, a common complication that may carry a risk of death, and acute liver failure, an exceedingly rare consequence of PCNL.</p><p><strong>Conclusion: </strong>In summary, while PCNL is a valuable technique for treating kidney stones, it is not without risk. This case underscores the importance of recognizing and managing rare complications following PCNL surgery, highlighting the need for vigilance, multidisciplinary care, and timely interventions to ensure favorable patient outcomes.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant chemohormonal therapy before radical prostatectomy in high-risk prostate cancer: a mini-review. 高危前列腺癌根治性前列腺切除术前的新辅助化疗:微型综述。
IF 1.2 Pub Date : 2024-02-15 eCollection Date: 2024-01-01
Junjie Fan, Zhangdong Jiang, Guojing Wang, Dalin He, Kaijie Wu

High-risk localized prostate cancer (PCa) has the potential of recurrence and progression to a lethal phenotype, and neoadjuvant therapy followed by radical prostatectomy (RP) may be an option for these patients. Docetaxel has been recently shown to be an effective chemotherapeutic agent for high-volume metastatic hormone-sensitive PCa and metastatic castration-resistant PCa, and these increased efficacy create the impetus to assess the potential role of preoperative docetaxel in high-risk localized PCa. In this mini-review, we found that neoadjuvant chemohormonal therapy (NCHT) may be an effective neoadjuvant regimen to improve oncological outcome of high-risk PCa. However, the addition of docetaxel in the neoadjuvant setting would unavoidably increase the rate of adverse events, impose additional economic burdens. Therefore, suitable patient selection is crucial and pathological response might be a surrogate endpoint. Furthermore, we also found that molecular imaging prostate-specific membrane antigen (PSMA) PET/CT was a promising tool to evaluation the effectiveness of NCHT, and the expression status of AR, AR-V7, Ki-67, PTEN and TP53 might be helpful for urologists to identify more suitable candidates for NCHT.

高危局部前列腺癌(PCa)有可能复发并发展为致命的表型,对这些患者来说,新辅助治疗后进行根治性前列腺切除术(RP)可能是一种选择。多西他赛最近已被证明是治疗高体积转移性激素敏感性PCa和转移性阉割耐药PCa的有效化疗药物,这些疗效的提高推动了对术前多西他赛在高危局部PCa中潜在作用的评估。在这篇微型综述中,我们发现新辅助化疗激素疗法(NCHT)可能是改善高危 PCa 肿瘤治疗效果的有效新辅助方案。然而,在新辅助治疗中加入多西他赛将不可避免地增加不良反应的发生率,并带来额外的经济负担。因此,选择合适的患者至关重要,病理反应可能是一个替代终点。此外,我们还发现,分子影像学前列腺特异性膜抗原(PSMA)PET/CT是评估NCHT疗效的有效工具,而AR、AR-V7、Ki-67、PTEN和TP53的表达状态可能有助于泌尿科医生识别更多适合NCHT的患者。
{"title":"Neoadjuvant chemohormonal therapy before radical prostatectomy in high-risk prostate cancer: a mini-review.","authors":"Junjie Fan, Zhangdong Jiang, Guojing Wang, Dalin He, Kaijie Wu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>High-risk localized prostate cancer (PCa) has the potential of recurrence and progression to a lethal phenotype, and neoadjuvant therapy followed by radical prostatectomy (RP) may be an option for these patients. Docetaxel has been recently shown to be an effective chemotherapeutic agent for high-volume metastatic hormone-sensitive PCa and metastatic castration-resistant PCa, and these increased efficacy create the impetus to assess the potential role of preoperative docetaxel in high-risk localized PCa. In this mini-review, we found that neoadjuvant chemohormonal therapy (NCHT) may be an effective neoadjuvant regimen to improve oncological outcome of high-risk PCa. However, the addition of docetaxel in the neoadjuvant setting would unavoidably increase the rate of adverse events, impose additional economic burdens. Therefore, suitable patient selection is crucial and pathological response might be a surrogate endpoint. Furthermore, we also found that molecular imaging prostate-specific membrane antigen (PSMA) PET/CT was a promising tool to evaluation the effectiveness of NCHT, and the expression status of AR, AR-V7, Ki-67, PTEN and TP53 might be helpful for urologists to identify more suitable candidates for NCHT.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140157292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of clinical and experimental urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1